Aligos Therapeutics, Inc.
$6.67
The Read: Aligos Therapeutics' stock declined about 12% after Q1 2026 earnings met expectations but failed to ease cash concerns, then dropped another 10% when HBV cure data showing 40% response was viewed as underwhelming.
ALGS
Hover to view data
No Data